Intrexon (XON) Shares Gap Down to $4.42

Intrexon Corp (NYSE:XON) shares gapped down prior to trading on Thursday . The stock had previously closed at $4.51, but opened at $4.42. Intrexon shares last traded at $4.33, with a volume of 2679732 shares changing hands.

Several research firms have commented on XON. Zacks Investment Research raised shares of Intrexon from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research note on Saturday, January 26th. JMP Securities reaffirmed a “buy” rating and set a $43.00 price objective on shares of Intrexon in a research note on Wednesday, March 6th. Finally, Northland Securities lowered shares of Intrexon from an “outperform” rating to a “market perform” rating in a research note on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $34.00.

Intrexon (NYSE:XON) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.28) EPS for the quarter, hitting the consensus estimate of ($0.28). The firm had revenue of $23.30 million for the quarter, compared to analysts’ expectations of $32.12 million. The firm’s quarterly revenue was down 41.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.36) earnings per share.

In other Intrexon news, major shareholder Randal J. Kirk sold 95,241 shares of Intrexon stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $0.65, for a total transaction of $61,906.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Randal J. Kirk sold 41,678 shares of Intrexon stock in a transaction on Monday, April 1st. The stock was sold at an average price of $0.67, for a total transaction of $27,924.26. The disclosure for this sale can be found here. Insiders have sold 362,419 shares of company stock valued at $1,032,421 over the last ninety days. 48.20% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in XON. Bank of New York Mellon Corp lifted its position in shares of Intrexon by 9.4% during the third quarter. Bank of New York Mellon Corp now owns 304,747 shares of the biotechnology company’s stock worth $5,247,000 after purchasing an additional 26,136 shares during the last quarter. Man Group plc bought a new stake in shares of Intrexon during the third quarter worth $225,000. MetLife Investment Advisors LLC lifted its position in shares of Intrexon by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 50,838 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 18,072 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Intrexon by 30.1% during the third quarter. Teachers Advisors LLC now owns 161,024 shares of the biotechnology company’s stock worth $2,773,000 after purchasing an additional 37,230 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Intrexon by 1.3% during the third quarter. Vanguard Group Inc. now owns 6,204,864 shares of the biotechnology company’s stock worth $106,847,000 after purchasing an additional 81,918 shares during the last quarter. Institutional investors and hedge funds own 84.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Intrexon (XON) Shares Gap Down to $4.42” was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.themarketsdaily.com/2019/05/11/intrexon-xon-shares-gap-down-to-4-42.html.

About Intrexon (NYSE:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Story: When is a capital gain realized?

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.